Pharmacological and pharmaceutical profile of gliclazide: A review

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 9, 2011, Pages 11-19

  Sarkar, Ananya ^a   Tiwari, Ajay ^a   Bhasin, Parminder S ^b   Mitra, Moloy ^b  

^a JAIPUR NATIONAL UNIVERSITY   (India)

^b RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Diabetes mellitus; Diabetic retinopathy.; Gliclazide; Oral hypoglycaemic agent; Tolerability

Indexed keywords

EID: 84875399372     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Akanuma Y , Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S ,Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas , Institute for Diabetes Care and Research, Asahi Life Foundation ,2009, 5 (3) 228-235.
2. Baba S. Double-blind randomized control study with gliclazide Clin Eva 1983; 11(1):51-94.
3. Boulevard Armand , Frappier Laval, SERVIER CANADA Inc. 235,Quebec H7V 4A7 Date of Approval: December, 1989 Date of Revision: May 25, 2011 Control No. 145114
4. Campbell DB, Adriaenssens PI, Hopkins YW, Gordon B, Williams JRB: Pharmacokinetics and metabolism of gliclazide. A review Royal Soc Med Int Congr Symp 1980; 20:71-82.
5. Campbell DB, Forette B, Rolland A, Hopkins Y, Gordon BH: Gliclazide pharmacokinetics in the elderly Excerpta Medica 1982; 577:8.
6. Chan TK, Chan V, Teng CS, Yeung RTT: Effets du gliclazide et du glibenclamide sur les fonctions plaquettaires, la fibrinolyse et I'équilibre glycémique chez des diabétiques présentant une rétinopathien Sem Hop Paris 1982; 58(19):1197-1200.
7. Chan TK, Ckan V, Teng CS, Yeung RTT: Progression of diabetic background retinopathy: the effect of gliclazide compared to glibenclamide and the relationship to haemobiological changes. Excerpta Medica 1982; 577:7.
8. Chiasson JL, Bergman RN, Verdy M, Hamet P, De Lean A: Study on effect of gliclazide on secretion and action of insulin in normal and type II diabetic humans Bull Int Diabete Fed 1987; 32(1):9-11.
9. Desnoyers P, Saint-Dizier D: The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties ArzneimitteIforsch 1972; 22:1691-1695.
10. Duhault J, Lebon F: Protective activity of S 1702 on the microvascular system in normal and diabetic rats ArzneimitteIforsch 1972; 22:1686-1690.
11. Duhault J, Regnault F, Boulanger M, Tisserand F: Prevention of experimental obstructions in the retinal microcirculation Ophtalmologica 1975; 170:345-352.
12. Futijani B, Maeda J, Tsuboi T et coll: Effect of glicIazide on prostaglandin I2 formation in normaI streptozotocin-induced diabetic animals Jpn J Pharmacol 1983; 33:965-970.
13. Gamstedt A, Fagerberg SE: Long-term metabolic effects of gliclazide in NIDDM FADL Publish 1987; 16-19.
14. Golay A, Broquet C, Chabot V, Studer S, Felber JP:Effets métaboliques du gliclazide chez le diabétique de type II Étude par calorimétrie indirect Schweiz Med Wochenschr 1984; 114(8):261-264.
15. Harrower A: Comparison of diabetic control in type 2 (noninsulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin 1985; 9:676-680.
16. Hoich RI, Ng FM: lnsulin-potentiating action of gliclazide (Diamicron) Pharmacol Res Commun 1986; 18(5):419-430.
17. Holmes B et coll: Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus Drugs 1984; 27:301-327.
18. Ings RMJ, Campbell B, Gordon BH, Beaufils M, Meyrier A, Jones R: The effet of renal disease on the pharmacokinetics of gliclazide in diabetic patients Br J Clin Pharmacol 1986; 21(5):572-573.
19. Jerums G et coll: Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study Diabetes Res CIin Pract 1987; 3:71-80.
20. Kilo C, Dudley J, Kalb E: Evaluation of safety and efficacy of gliclazide in non-insulin-dependent diabetic patients Bull Int Diabete Fed 1987; 32(1):27-29.
21. Kosaka K et coll: Clinical comparative study on the therapeutic effects of oral hypoglycaemic agents in patients with diabetic retinopathy J Jpn Diab Soc 1983; 26(5):531-540.
22. Kuwashima J et coll: Inhibition by gliclazide of platelet adhesiveness and aggregation in the rabbit made diabetic by alloxan Yakugaku Zasshi 1979; 99(1):50-64.
23. Larkins R, Jerums G, Taft JL Godfrey H, Smith IL, Martin TJ: Lack of effect of gliclazide on platelet aggregation in insulin-treated and non- insulintreated diabetes: a two-year controlled study Diabetes Res Clin Pract 1988; 4:81-87.
24. Samina A. Jamadar, Snehal P. Mulye, Poonam S. Karekar , Yogesh V. Pore, Kishor B. Burade Development and validation of UV spectrophotometric method for the determination of Gliclazide in tablet dosage form. Der Pharma Chemica, 2011, 3 (4):338-343.
25. Serradas P, Bailbe D, Portha B: Long-term gIiclazide treatment improves the in-vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin, Diabetologia sept. 1989 , 55-57
26. Shimizu M, Tsuboi J, Fujitani B et coll: Pharmacological studies on gliclazide. Effects of gliclazide on platelet aggregation, adhesion and blood coagulation Pharmacometrics 1976; 12(2):295-302
27. Tourniaire J, Orgiazzi J: Gliclazide and thyroid function, an experimental and clinical study Royal Soc Med Int Congr Symp 1980:151- 155
28. Tsuboi T, Fujitani B, Maeda J et coll: Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea pig platelets Thromb Res 1981; 21:103-110
29. Turner RC, Hoskerj P, Rudenski AS, Burnett MA, Matthews DR: Similar reduction of first and second phase B-cell responses at three different glucose levels in type II diabetes, and the effect of gliclazide therapy Metabolism 1989; 38(5):107-110
30. Yasuo Akanuma, Kinori Kosaka, Yasunori Kanazawa, Masato Kasuga, Masatoshi Fukuda, Shigenobu Aoki : Long-term comparison of oral hypoglycemic agents in diabetic retinopathy Gliclazide vs. other sulfonylureas, Diabetes Research and Clinical Practice, Volume 5, Issue 2, 13 July 1988 , 81-90